Highlights Intra-Cellular Therapies, Inc.

Equities

ITCI

US46116X1019

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
73.26 ^USD	+1.57%		+1.23%	+2.29%

Apr. 23	Canaccord Genuity Raises Intra-Cellular Therapies' Price Target to $107 From $100, Maintains Buy Rating	MT
Apr. 22	Needham & Co Adjusts Intra-Cellular Therapies Price Target to $90 From $82, Maintains Buy Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Intra-Cellular Therapies Prices $500 Million Stock Offering	Apr. 18	MT
Intra-Cellular Therapies Launches $500 Million Public Offering of Stock; Shares Edge Lower in Late Trade	Apr. 16	MT
Sector Update: Health Care Stocks Higher Late Afternoon	Apr. 16	MT
Top Midday Gainers	Apr. 16	MT
Intra-Cellular Therapies Stock Jumps After Major Depressive Disorder Treatment Study Shows Positive Results	Apr. 16	MT
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder	Apr. 16	CI
Intra-Cellular Therapies Q4 Loss Narrows, Revenue Increases	Feb. 22	MT
Intra-Cellular Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Reports Q4 Revenue $132.1M	Feb. 22	MT
Intra-Cellular Therapies, Inc. Provides Earnings Guidance for the Full Year 2024	Feb. 22	CI
Intra-Cellular Therapies, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Reports Q3 Revenue $126.2M	Nov. 02	MT
Intra-Cellular Therapies, Inc. Provides Sales Guidance for the Fiscal Year 2023	Nov. 02	CI
Intra-Cellular Therapies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Intra-Cellular Therapies Narrows Q2 Net Loss, Doubles Revenue	23-08-03	MT
Intra-Cellular Therapies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Posts Q2 Revenue $110.8M	23-08-03	MT
Intra-Cellular Therapies, Inc. Provides Earnings Guidance for the Full Year 2023	23-08-03	CI
Intra-Cellular Therapies, Inc. Announces CAPLYTA Data Presentations At the American Society of Clinical Psychopharmacology Annual Meeting	23-05-31	CI
Intra-Cellular Therapies Q1 Net Loss Narrows, Revenue More Than Doubles	23-05-04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Intra-Cellular Therapies, Inc.

Equities

ITCI

US46116X1019

Highlights

Filters